

Update re. EKF distribution of shares in Verici Dx
RNS Number : 4215A
Verici Dx PLC
24 May 2023

Verici Dx plc
("Verici Dx" or the "Company")

Update re. EKF distribution of shares in Verici Dx

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes this morning's announcement from EKF Diagnostics Holdings plc ("EKF") which confirms that EKF has written to certain EKF Shareholders with regard to the distribution of ordinary Verici shares previously held by EKF.

The full text of the announcement from EKF is reproduced below:

Distribution of shares in Verici Dx plc

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that in accordance with the announcement dated 20 June 2022 (the "June 2022 Announcement")¹ in relation to the distribution of certain shares it held in Verici Dx plc (the "Verici Dividend Shares"), it is today writing to certain Relevant EKF Shareholders² who, at the record date for the distribution, held their qualifying interest in EKF via CREST (a Qualifying CREST Account).

The letter sets out instructions as to how such persons may elect to receive all of their Verici Dividend Shares by way of transfer into their Qualifying CREST Account following the expiry of the lock-up period as described in the June 2022 Announcement.

In the event that no request for transfer into a Qualifying CREST Account is made, a Relevant EKF Shareholder will automatically receive their Verici Dividend Shares in certificated form, which may take up to 10 business days from the expiry of the lock-up period.

Notes:

1. <https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862>
2. A Relevant EKF Shareholder is defined in the June 2022 Announcement as an EKF shareholder who was on the register at the close of business on 24 June 2022, being the record date for the distribution of the Verici Dividend Shares; only those investors who held their EKF interests via CREST at that time are eligible to elect to receive their Verici Dividend Shares into their Qualifying CREST Account.
3. If you are the holder of a Qualifying CREST Account and do not receive any correspondence regarding this matter, please contact LINK as the Company's receiving agent on the number below.

Enquiries:

Verici Dx
Sara Barrington, CEO
Julian Baines, Chairman

www.vericidx.com
Via Walbrook PR

Link Group (Registrars)

Tel: +44 371 664 0391 or
shareholderenquiries@linkgroup.co.uk

**Singer Capital Markets (Nominated Adviser & Tel: +44 20 7496 3000
Broker)**

Aubrey Powell / Sam Butcher

Walbrook PR Limited

Paul McManus / Stephanie Cuthbert /
Sam Allen

Tel: +44 20 7933 8780
or vericidx@walbrookpr.com
Mob: +44 7980 541 893 / +44 7796 794 663 /
07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Clarava™, a pre-transplant prognosis test for the risk of early acute rejection, and Tutivia™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSEEESEDESESI